Alternatively, when chemiluminescent probes are utilized, direct measurement of light emission decay provides the analytical signal (Uotila et al., 1994)
Until recent years, treatment options for managing this disease were limited
Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, glucagon) that remains unlicensed in the UK, with no MHRA approval, no NHS availability, and no BNF listing as of 20242025
This isn't contract manufacturing, either: it's complete vertical integration that ensures quality control from raw materials through finished product
The concept is that patients could achieve significant weight loss on higher doses and then step down to 4mg to maintain results with fewer side effects
Peter gives his take on this possibility and reviews data from a more recent study investigating the question of whether metformin should be used for general geroprotection. If youre not a subscriber and listening on a podcast player, youll only be able to hear a preview of the AMA